The aim of this study was to assess the effects on lipids and safety during a 12-week reversal period after 18 months of treatment with anacetrapib. The cholesteryl ester transfer protein inhibitor anacetrapib was previously shown to reduce low-density lipoprotein cholesterol by 39.8% (estimated using the Friedewald equation) and increase high-density lipoprotein (HDL) cholesterol by 138.1%, with an acceptable side-effect profile, in patients with or at high risk for coronary heart disease in the Determining the Efficacy and Tolerability of CETP Inhibition With Anacetrapib (DEFINE) trial. A total of 1,398 patients entered the 12-week reversal-phase study, either after completion of the active-treatment phase or after early discontinuation o...
As delineated in this review, cholesteryl ester transfer protein (CETP) contributes to an atherogeni...
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular ...
In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been ass...
BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density l...
BACKGROUND: In the Determining the Efficacy and Tolerability of cholesteryl ester transfer protein (...
Dylan L Steen,1 Amit V Khera,2 Christopher P Cannon1 1TIMI Study Group, Cardiovascular Division, 2De...
Cholesteryl ester transfer protein (CETP) inhibitors significantly increase serum high-density lipop...
Background: Residual cardiovascular (CV) risk often remains high despite statin therapy to lower low...
BACKGROUND Patients with atherosclerotic vascular disease remain at high risk for cardiovascular eve...
Background Patients with prior vascular disease remain at high risk for cardiovascular events despit...
High-density lipoprotein cholesterol(HDL-C) in plasma has been recog-nized as inversely related to r...
Evacetrapib, a new cholesteryl ester transfer protein inhibitor, is being investigated as a potentia...
Introduction: While some cholesteryl ester transfer protein inhibitors have had their clinical study...
To assess the effects of anacetrapib added to statin ± other lipid-modifying therapies in patients w...
Objective—Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein ...
As delineated in this review, cholesteryl ester transfer protein (CETP) contributes to an atherogeni...
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular ...
In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been ass...
BACKGROUND: Anacetrapib is a cholesteryl ester transfer protein inhibitor that raises high-density l...
BACKGROUND: In the Determining the Efficacy and Tolerability of cholesteryl ester transfer protein (...
Dylan L Steen,1 Amit V Khera,2 Christopher P Cannon1 1TIMI Study Group, Cardiovascular Division, 2De...
Cholesteryl ester transfer protein (CETP) inhibitors significantly increase serum high-density lipop...
Background: Residual cardiovascular (CV) risk often remains high despite statin therapy to lower low...
BACKGROUND Patients with atherosclerotic vascular disease remain at high risk for cardiovascular eve...
Background Patients with prior vascular disease remain at high risk for cardiovascular events despit...
High-density lipoprotein cholesterol(HDL-C) in plasma has been recog-nized as inversely related to r...
Evacetrapib, a new cholesteryl ester transfer protein inhibitor, is being investigated as a potentia...
Introduction: While some cholesteryl ester transfer protein inhibitors have had their clinical study...
To assess the effects of anacetrapib added to statin ± other lipid-modifying therapies in patients w...
Objective—Lp(a) [lipoprotein (a)] is composed of apoB (apolipoprotein B) and apo(a) [apolipoprotein ...
As delineated in this review, cholesteryl ester transfer protein (CETP) contributes to an atherogeni...
BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular ...
In observational analyses, higher levels of high-density lipoprotein (HDL) cholesterol have been ass...